Avodart Adverse Reactions

Clinical Trial Data: AVODART Monotherapy for BPH: The following investigator-judged drug-related adverse events (with incidence ≥1%) have been reported more commonly in the three phase III placebo-controlled studies on AVODART treatment compared to placebo: (see Table 1.)

Click on icon to see table/diagram/image

No change to the adverse event profile was apparent over a further 2 years in open-label extension studies.
Avodart and Tamsulosin Combination Therapy for BPH: The following investigator-judged drug-related adverse events (with a cumulative incidence of greater or equal to 1%) have been reported in the CombAT (Combination of AVODART and Tamsulosin) Study, a comparison of AVODART 0.5 mg and tamsulosin 0.4 mg once daily for four years in combination or as monotherapy. (See Table 2.)

Click on icon to see table/diagram/image

Post-marketing Data: Adverse drug reactions are listed as follows by system organ class and frequency. Frequencies are defined as: Very common (≥1/10), common (≥1/100 and <1/10), uncommon (≥1/1000 and <1/100), rare (≥1/10,000 and <1/1000) and very rare (<1/10,000) including isolated reports. Frequency categories determined from post-marketing data refer to reporting rate rather than true frequency.
Immune system disorders: Very rare: Allergic reaction, including rash, pruritus, urticaria, localised oedema, and angioedema.
Psychiatric disorders: Very rare: Depressed mood.
Skin and subcutaneous tissue disorders: Rare: Alopecia (primarily body hair loss), Hypertrichosis.
Reproductive system and breast disorders: Very rare: Testicular pain and testicular swelling.